3.80Open3.80Pre Close0 Volume0 Open Interest20.00Strike Price0.00Turnover0.00%IV-86.85%PremiumJan 17, 2025Expiry Date11.33Intrinsic Value100Multiplier20DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.82Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Kura Oncology Stock Discussion
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology | KURA Stock News
$Kura Oncology (KURA.US)$
No comment yet